UroGen Pharma Ltd.
URGN
$24.38
-$4.08-14.34%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 96.52M | 94.24M | 91.87M | 90.40M | 89.36M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 96.52M | 94.24M | 91.87M | 90.40M | 89.36M |
| Cost of Revenue | 11.63M | 10.80M | 9.48M | 8.88M | 8.70M |
| Gross Profit | 84.89M | 83.43M | 82.39M | 81.52M | 80.67M |
| SG&A Expenses | 149.51M | 140.87M | 127.72M | 120.05M | 110.85M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 228.82M | 216.70M | 198.73M | 186.08M | 173.10M |
| Operating Income | -132.31M | -122.47M | -106.86M | -95.68M | -83.73M |
| Income Before Tax | -161.64M | -150.82M | -135.26M | -124.04M | -111.34M |
| Income Tax Expenses | 3.00M | 4.15M | 3.17M | 2.83M | 4.04M |
| Earnings from Continuing Operations | -164.64 | -154.97 | -138.43 | -126.87 | -115.38 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -164.64M | -154.97M | -138.43M | -126.87M | -115.38M |
| EBIT | -132.31M | -122.47M | -106.86M | -95.68M | -83.73M |
| EBITDA | -131.11M | -122.18M | -106.58M | -95.35M | -83.28M |
| EPS Basic | -3.46 | -3.27 | -3.05 | -3.00 | -2.92 |
| Normalized Basic EPS | -2.11 | -1.98 | -1.85 | -1.82 | -1.76 |
| EPS Diluted | -3.46 | -3.27 | -3.05 | -3.00 | -2.92 |
| Normalized Diluted EPS | -2.11 | -1.98 | -1.85 | -1.82 | -1.76 |
| Average Basic Shares Outstanding | 190.25M | 188.97M | 181.73M | 171.37M | 160.49M |
| Average Diluted Shares Outstanding | 190.25M | 188.97M | 181.73M | 171.37M | 160.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |